MONALEESA-7: Ribociclib Plus Endocrine Therapy in Hormone-Receptor–Positive, HER2-Negative Advanced Breast Cancer

⚠️ Updated analysis. The primary endpoint (investigator-assessed progression-free survival) was previously reported (Tripathy et al., Lancet Oncol 2018). This analysis reports overall survival at a median follow-up of 34.6 months.

Overall survival (42 months, ITT): 70.2% vs 46.0% — HR 0.71 (95% CI 0.54–0.95; P=0.00973) Exploratory (PFS2, 42 months): 54.6% vs 37.8% — HR 0.69 (95% CI 0.55–0.87) Safety signal: Grade 3 or 4 neutropenia (63.5% ribociclib vs 4.5% placebo)

📱 Clinic quick reference: Mobile version — save for point-of-care use

Clinical Bottom Line

MONALEESA-7 demonstrated that adding ribociclib to endocrine therapy plus ovarian suppression significantly prolonged overall survival in premenopausal and perimenopausal women with hormone-receptor–positive, HER2-negative advanced breast cancer. This was the first CDK4/6 inhibitor trial to show a statistically significant overall survival benefit in any breast cancer population at the time of publication, and it remains a landmark result that specifically addresses the premenopausal/perimenopausal population — a group historically underrepresented in first-line endocrine therapy trials.

The survival benefit was observed in the context of first-line therapy for advanced disease. Ribociclib combined with a nonsteroidal aromatase inhibitor plus goserelin, or with tamoxifen plus goserelin, is now firmly established in the current treatment algorithm for premenopausal women with HR+/HER2− advanced breast cancer. CDK4/6 inhibitor–based first-line endocrine therapy is the standard of care, with MONALEESA-7 providing the strongest survival evidence for ribociclib in this menopausal subpopulation.

Neutropenia is the dominant toxicity — expected, predictable, and manageable with dose modifications, but requiring routine monitoring. Hepatobiliary toxicity and QT prolongation warrant ECG surveillance and liver function testing per prescribing information, particularly in a young patient population that may be on concomitant medications.

Trial Overview

Study Design

• Trial name and registration: MONALEESA-7 (NCT02278120)
• Design: Phase 3, randomized, double-blind, placebo-controlled trial; prespecified interim analysis of overall survival (second interim analysis)
• Randomization: 1:1 ratio; stratified by presence or absence of liver or lung metastases, previous chemotherapy for advanced disease (yes or no), and endocrine therapy partner (tamoxifen plus goserelin or an aromatase inhibitor plus goserelin)
• Setting: Hormone-receptor–positive, HER2-negative advanced breast cancer (locoregionally recurrent or metastatic); first-line endocrine therapy
• Enrollment period: December 17, 2014, to August 1, 2016

This publication reports the protocol-specified second interim analysis of overall survival in the MONALEESA-7 trial. The primary endpoint of investigator-assessed progression-free survival was previously reported [4]. Because the prespecified efficacy stopping boundary was crossed at this interim analysis, the overall survival results are considered final per protocol.

Mechanism of Action

Ribociclib is an oral, selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By blocking CDK4/6, ribociclib inhibits retinoblastoma protein phosphorylation, preventing cell-cycle progression from G1 to S phase in estrogen receptor–positive breast cancer cells. The combination with endocrine therapy (aromatase inhibitor or tamoxifen) and ovarian function suppression (goserelin) targets the estrogen signaling and cell-cycle proliferation pathways concurrently [2].

Patient Population

• Key eligibility: Women aged 18 to 59 years; premenopausal or perimenopausal at trial entry; histologically or cytologically confirmed HR+/HER2− advanced breast cancer (locoregionally recurrent or metastatic, not amenable to curative therapy); ECOG performance-status score of 0 or 1; measurable disease per RECIST v1.1 or at least one predominantly lytic bone lesion; no previous endocrine therapy in the advanced disease setting; no more than one previous line of chemotherapy for advanced disease; no previous CDK4/6 inhibitor treatment
• Biomarker selection: Hormone-receptor–positive, HER2-negative
• Sample size flow: 672 patients randomized (335 ribociclib, 337 placebo) in the intention-to-treat population. Number screened was not reported in this publication. Safety population size was not reported in this publication (detailed safety data were in the Supplementary Appendix).

Baseline Characteristics

Baseline characteristics were reported in Table S1 of the Supplementary Appendix, which was not available for extraction. Detailed baseline demographics and disease characteristics are not reported in this publication.

Treatment Protocol

Experimental Arm: Ribociclib (n=335 randomized)

Ribociclib plus goserelin plus either a nonsteroidal aromatase inhibitor (letrozole or anastrozole) or tamoxifen. - Dose and schedule: Ribociclib 600 mg orally once daily for 21 consecutive days, followed by 7 days off (28-day cycle); goserelin 3.6 mg subcutaneously on day 1 of each 28-day cycle; letrozole 2.5 mg or anastrozole 1 mg or tamoxifen 20 mg orally once daily continuously - Treatment duration: Not reported in this publication - Median treatment duration: Approximately 2 years - Median relative dose intensity: Not reported in this publication

At the time of data analysis, 116 of 335 patients (34.6%) in the ribociclib group were still receiving trial treatment.

Control Arm: Placebo (n=337 randomized)

Placebo plus goserelin plus either a nonsteroidal aromatase inhibitor (letrozole or anastrozole) or tamoxifen. - Dose and schedule: Matching placebo orally once daily for 21 consecutive days, followed by 7 days off (28-day cycle); goserelin 3.6 mg subcutaneously on day 1 of each 28-day cycle; letrozole 2.5 mg or anastrozole 1 mg or tamoxifen 20 mg orally once daily continuously - Treatment duration: Not reported in this publication - Median treatment duration: Approximately 1 year

At the time of data analysis, 57 of 337 patients (16.9%) in the placebo group were still receiving trial treatment. A total of 173 patients were still receiving trial treatment across both arms.

Efficacy Outcomes

The primary endpoint of this trial (investigator-assessed progression-free survival) was reported in the original publication [4]. The current analysis, with a median follow-up of 34.6 months (minimum 28.0 months), reports the prespecified second interim analysis of overall survival and exploratory endpoints.

Key Secondary Endpoint: Overall Survival

Definition: Time from randomization to death from any cause Analysis population: Intention-to-treat (N=672) Statistical method: Stratified Cox proportional-hazards model and stratified log-rank test (one-sided); three-look group sequential design with Lan–DeMets (O'Brien–Fleming) stopping boundaries Formally tested: Yes — part of the hierarchical testing strategy controlling family-wise type 1 error rate at 2.5% (one-sided)

Ribociclib: 42-month Kaplan–Meier overall survival 70.2% (95% CI, 63.5 to 76.0); 83 deaths among 335 patients (24.8%) Placebo: 42-month Kaplan–Meier overall survival 46.0% (95% CI, 32.0 to 58.9); 109 deaths among 337 patients (32.3%) Comparison: HR 0.71 (95% CI, 0.54 to 0.95; P=0.00973)

The one-sided stratified log-rank P value of 0.00973 crossed the prespecified stopping boundary of P=0.01018, establishing superior overall survival for ribociclib.

Landmark Kaplan–Meier estimates:

Median overall survival: Not estimable (NE) in the ribociclib group; 40.9 months (95% CI, 37.8–NE) in the placebo group.

Multiplicity control: This analysis was the second of three planned interim analyses. The first interim analysis was performed after 89 deaths (approximately 35% of the 252 planned deaths), using a P value threshold of 0.00016 (not crossed). The second interim analysis was performed after 192 deaths (approximately 75% information fraction), using a P value threshold of 0.01018 (crossed). Because the efficacy stopping boundary was crossed, the overall survival results are considered final per protocol.

Overall Survival by Endocrine Therapy Partner

Among the 495 patients who received a nonsteroidal aromatase inhibitor (NSAI) plus goserelin: - Ribociclib (n=248): 42-month OS 69.7% (95% CI, 61.3 to 76.7); 61 deaths (24.6%) - Placebo (n=247): 42-month OS 43.0% (95% CI, 25.9 to 59.0); 80 deaths (32.4%) - HR: 0.70 (95% CI, 0.50 to 0.98)

Among the 177 patients who received tamoxifen plus goserelin: - Ribociclib (n=87): 42-month OS 71.2% (95% CI, 58.0 to 80.9); 22 deaths (25.3%) - Placebo (n=90): 42-month OS 54.5% (95% CI, 36.0 to 69.7); 29 deaths (32.2%) - HR: 0.79 (95% CI, 0.45 to 1.38)

Exploratory Endpoints

Progression-Free Survival During Receipt of Second-Line Therapy (PFS2)

Definition: Time from randomization to the first documented disease progression while the patient was receiving second-line therapy (as reported by the physician) or death from any cause, whichever occurred first Analysis population: Intention-to-treat

• Events: 126 of 335 patients (37.6%) in the ribociclib group and 161 of 337 (47.8%) in the placebo group; 287 total events
• 42-month PFS2 rate:
• Ribociclib: 54.6% (95% CI, 46.8 to 61.8)
• Placebo: 37.8% (95% CI, 28.4 to 47.2)
• Comparison: HR 0.69 (95% CI, 0.55 to 0.87)
• Median PFS2: NE (ribociclib) vs 32.3 months (placebo)

This endpoint was exploratory and was not formally tested in the statistical hierarchy.

Time to First Subsequent Chemotherapy

Definition: Time from randomization to the beginning of the first chemotherapy after discontinuation of the trial regimen Analysis population: Intention-to-treat

• 42-month rate of patients not yet having received first subsequent chemotherapy:
• Ribociclib: 65.8% (95% CI, 59.1 to 71.7)
• Placebo: 49.0% (95% CI, 41.1 to 56.3)
• Comparison: HR 0.60 (95% CI, 0.46 to 0.77)

This endpoint was exploratory and was not formally tested in the statistical hierarchy.

Subsequent Therapy

A total of 219 patients in the ribociclib group and 280 patients in the placebo group discontinued the trial regimen. Among these, the percentage receiving subsequent antineoplastic therapies was similar: 151 patients (68.9%) in the ribociclib group and 205 (73.2%) in the placebo group.

Type of first subsequent therapy:

Most common subsequent therapies (all subsequent lines):

• Pyrimidine analogues: 29.7% (ribociclib) vs 33.6% (placebo)

• Aromatase inhibitors: 29.2% vs 27.5%

• Taxanes: 24.2% vs 26.8%

• Antiestrogens: 23.3% vs 25.4%

CDK4/6 inhibitors were used as subsequent therapy in 10.0% of ribociclib patients vs 18.6% of placebo patients. A total of 234 patients received chemotherapy as a subsequent therapy at any time (95 ribociclib, 139 placebo).

Safety

Safety Population

The safety population size per arm was not reported in this publication. Detailed safety data were provided in Table S3 of the Supplementary Appendix (not available for extraction).

Safety Summary

Fewer than 4 standard summary safety fields were reported in this publication. The following narrative summarizes the available safety data:

Adverse events remained consistent with those reported in the primary analysis [4]. No new safety signals were observed after a median of approximately 2 years of treatment exposure in the ribociclib group. Standard summary safety metrics — including rates of any adverse event, any grade ≥3 adverse event, serious adverse events, treatment-related adverse events, discontinuation due to adverse events, dose reductions, dose interruptions, and treatment-related deaths — were not reported in this publication (these data were referenced as Table S3 in the Supplementary Appendix).

Grade ≥3 Adverse Events of Clinical Significance

The publication reported key grade 3 or 4 adverse events of special interest:

Grade fidelity note: The source reports these as "grade 3 or 4" combined. Grade 3 and grade 4 were not reported separately in this publication.

Adverse Events of Special Interest

⚠️ Neutropenia: Critical Safety Signal

• Any grade: Not reported in this publication
• Grade 3 or 4: 63.5% (ribociclib) vs 4.5% (placebo)
• Grade 5 (fatal): Not reported in this publication
• Clinical implication: Neutropenia is the most common high-grade toxicity with ribociclib. Routine complete blood count monitoring is required per prescribing information, with dose modifications for grade 3/4 neutropenia [2]. Despite the high incidence of laboratory neutropenia, febrile neutropenia rates are typically low with CDK4/6 inhibitors.

QT-Interval Prolongation

• Any grade: Not reported in this publication
• Grade 3 or 4: 1.8% (ribociclib) vs 1.2% (placebo)
• Management: No instances of symptomatic arrhythmias or torsades de pointes were observed. ECG monitoring is required per prescribing information [2].
• Clinical implication: While the incidence of grade 3 or 4 QT prolongation was low, this remains a ribociclib-specific concern among CDK4/6 inhibitors, particularly relevant when prescribing concomitant QT-prolonging medications.

Deaths

• Total deaths: 192 (83 ribociclib [24.8%], 109 placebo [32.3%])
• Treatment-related deaths: Not reported in this publication

Subgroup Analyses

Exploratory subgroup analyses of overall survival were prespecified and are presented from Figure 2 of the publication. The overall treatment effect (HR 0.71) was generally consistent across subgroups.

Notable observations:

• The benefit of ribociclib was observed across most subgroups, with the point estimate of the hazard ratio favoring ribociclib in nearly all prespecified analyses.
• The bone-only disease subgroup showed no apparent survival benefit (HR 1.00; 95% CI, 0.53–1.93), while patients with non-bone-only disease appeared to derive benefit (HR 0.65; 95% CI, 0.47–0.90).
• The Asian subgroup showed a notably pronounced treatment effect (HR 0.40; 95% CI, 0.22–0.72), while non-Asian patients showed a more attenuated signal (HR 0.91; 95% CI, 0.64–1.30).
• Patients who had not received prior adjuvant/neoadjuvant chemotherapy appeared to derive greater benefit (HR 0.54; 95% CI, 0.32–0.91) compared with those who had (HR 0.91; 95% CI, 0.60–1.36).
• The small subgroup with disease progression >12 months after prior endocrine therapy showed a hazard ratio of 1.53 (95% CI, 0.44–5.34) with only 60 patients; this result is unreliable due to extremely limited sample size.

Interaction p-values were not reported for any subgroup.

These subgroup analyses were prespecified exploratory analyses and were not powered for formal statistical comparisons. Results should be interpreted as hypothesis-generating.

Key Comparator Trials

Cross-trial comparisons are limited by differences in patient populations, trial designs, and endpoints. These data are presented for context, not for direct statistical comparison.

Contextual Notes

MONALEESA-7 is unique among the pivotal CDK4/6 inhibitor trials in that it exclusively enrolled premenopausal and perimenopausal women and mandated ovarian function suppression with goserelin in both arms. This population has historically been underrepresented in first-line endocrine therapy trials for advanced breast cancer, as the MONALEESA-2, PALOMA-2, and MONARCH 3 trials enrolled postmenopausal women.

Critically, MONALEESA-7 was the first randomized CDK4/6 inhibitor trial to demonstrate a statistically significant overall survival benefit at the time of this 2019 publication. Subsequent analyses of MONALEESA-2 [5] and MONARCH 3 also reported overall survival data. The survival benefit in MONALEESA-7 was observed despite the fact that 18.6% of placebo patients received a CDK4/6 inhibitor as subsequent therapy, which would be expected to dilute any OS difference.

The trial also permitted either an aromatase inhibitor or tamoxifen as the endocrine partner, providing data on tamoxifen-based combinations that is not available from other CDK4/6 inhibitor trials. The subgroup receiving tamoxifen plus goserelin showed a numerically favorable but statistically non-significant hazard ratio for OS (HR 0.79; 95% CI, 0.45–1.38), while the NSAI plus goserelin subgroup showed a statistically significant benefit (HR 0.70; 95% CI, 0.50–0.98).

Grey Zones and Unanswered Questions

• Optimal endocrine partner for premenopausal women: While both the NSAI and tamoxifen subgroups showed point estimates favoring ribociclib, the trial was not powered to compare endocrine partners directly. The tamoxifen subgroup (n=177) showed a wider confidence interval that crossed unity. Whether an NSAI plus goserelin is superior to tamoxifen plus goserelin as the backbone endocrine therapy in this combination remains unresolved by this trial.

• Bone-only disease: The subgroup with bone-only metastases showed no apparent survival benefit from ribociclib (HR 1.00). While underpowered, this observation raises the question of whether bone-only disease — typically an indolent phenotype — derives meaningful benefit from CDK4/6 inhibitor addition, or whether the natural history is already favorable enough that incremental benefit is harder to detect.

• Asian vs non-Asian treatment effect: The striking difference in OS hazard ratios between Asian patients (HR 0.40) and non-Asian patients (HR 0.91) is unexplained. Potential confounders include differences in disease biology, subsequent therapy access, body weight and drug exposure, and sample size limitations. Whether this reflects a true pharmacogenomic or biologic difference or is a statistical artifact of subgroup analysis is unknown.

• Baseline characteristics not available: The Supplementary Appendix containing baseline characteristics (Table S1) was not provided in the main publication body. Without detailed baseline data, it is difficult to assess balance between arms for prognostic factors such as visceral disease burden, disease-free interval, number of metastatic sites, and prior therapy details.

• Optimal duration of CDK4/6 inhibitor therapy: MONALEESA-7 treated patients until disease progression. Whether there is a role for time-limited CDK4/6 inhibitor therapy (e.g., 2 years, analogous to adjuvant paradigms) in patients with sustained response is not addressed by this trial. Given the median treatment duration of approximately 2 years in the ribociclib arm, this question has practical relevance.

• Safety population and detailed AE data: The safety population size was not reported in this publication, and detailed adverse event data were provided only in the Supplementary Appendix. Standard summary safety metrics (any AE, serious AE, discontinuation due to AE, dose reductions) are not available from this publication, limiting a complete safety assessment.

Clinical Implications

Where This Fits in the Treatment Sequence

MONALEESA-7 established ribociclib plus endocrine therapy plus ovarian function suppression as a first-line treatment for premenopausal/perimenopausal women with HR+/HER2− advanced breast cancer. Current NCCN guidelines [3] recommend CDK4/6 inhibitor–based endocrine therapy as the preferred first-line approach for this population. Ribociclib is one of three CDK4/6 inhibitors (alongside palbociclib and abemaciclib) with category 1 evidence in this setting, but MONALEESA-7 provides the most direct evidence for the premenopausal population specifically, and the strongest OS data among the three agents in this subgroup.

Practical Considerations

• Ovarian function suppression is mandatory: All patients in MONALEESA-7 received goserelin. This trial does not support CDK4/6 inhibitor use in premenopausal women without concurrent ovarian suppression.
• ECG monitoring: Ribociclib's QT-prolongation risk requires ECG assessment at baseline, approximately day 14 of cycle 1, and at the beginning of cycle 2, with additional monitoring as clinically indicated [2]. This is a distinguishing safety consideration compared with palbociclib and abemaciclib.
• Liver function monitoring: Hepatobiliary toxic effects occurred at grade 3 or 4 in 11% of ribociclib patients. Liver function tests should be monitored per prescribing information [2].
• Neutropenia management: While grade 3 or 4 neutropenia occurred in 63.5% of ribociclib patients, this is primarily a laboratory finding managed with dose interruptions and reductions. Complete blood counts are required before each cycle and as clinically indicated [2].
• Endocrine partner choice: The NSAI subgroup showed a statistically significant OS benefit, while the tamoxifen subgroup did not reach significance. Current practice favors an aromatase inhibitor plus ovarian suppression in combination with a CDK4/6 inhibitor for premenopausal women, though tamoxifen remains an option where aromatase inhibitors are contraindicated.

Impact of Subsequent CDK4/6 Inhibitor Use on Results

Crossover from placebo to ribociclib was not permitted. However, 18.6% of placebo patients received a CDK4/6 inhibitor as subsequent therapy, compared with 10.0% of ribociclib patients. This degree of post-progression CDK4/6 inhibitor access in the control arm would be expected to attenuate the observed OS difference. The true survival benefit of first-line ribociclib may be larger than the measured HR of 0.71 suggests.

Post-Progression Options

Among patients who discontinued the trial regimen, subsequent antineoplastic therapy rates were similar between arms (68.9% ribociclib vs 73.2% placebo). Chemotherapy alone was the first subsequent therapy in 22.4% (ribociclib) vs 28.6% (placebo), suggesting that ribociclib may delay the need for chemotherapy. This is further supported by the exploratory time-to-first-subsequent-chemotherapy analysis (HR 0.60; 95% CI, 0.46–0.77), with 65.8% of ribociclib patients vs 49.0% of placebo patients free from subsequent chemotherapy at 42 months.

Unanswered Questions

The two most practice-relevant open questions are: (1) whether the survival benefit seen with ribociclib plus NSAI plus goserelin is generalizable to the tamoxifen combination, given the overlapping confidence intervals and small tamoxifen subgroup; and (2) whether bone-only disease truly does not benefit from CDK4/6 inhibitor addition, or whether longer follow-up would reveal a delayed separation of survival curves in this indolent subgroup.

Regulatory and Guideline Status

Regulatory

• FDA: Ribociclib (Kisqali) is approved in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women and adult men with HR+/HER2− advanced or metastatic breast cancer as initial endocrine-based therapy. The MONALEESA-7 trial supported the indication in premenopausal/perimenopausal women. Ribociclib also has approvals in combination with fulvestrant for certain settings.
• EMA: Ribociclib (Kisqali) is approved in combination with an aromatase inhibitor or fulvestrant for women with HR+/HER2− locally advanced or metastatic breast cancer.

⚠️ Regulatory status verified as of March 2026. Confirm current approval status and labeled indications before clinical use at FDA.gov.

Guidelines

• NCCN: Ribociclib plus aromatase inhibitor plus ovarian suppression is listed as a preferred first-line regimen for premenopausal women with HR+/HER2− metastatic breast cancer (Category 1) [3].

Companion Diagnostics

HR+/HER2− status is required per indication. Standard immunohistochemistry and/or FISH testing for ER, PR, and HER2 status are required; no novel companion diagnostic is needed.

About the Author

Andrew Stevenson is the founder and systems architect of kill-cancer.com, a clinical intelligence platform delivering structured, source-traced oncology trial analysis to practicing clinicians. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces directly to its source publication. Zero calculation. Zero editorializing. Zero hallucination.

Five siblings lost to cancer built the urgency. The engineering builds the trust.

📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum

Disclaimer

This article is intended for healthcare professionals only. It is not medical advice and should not be used as a substitute for professional clinical judgment. Treatment decisions should be made in consultation with qualified healthcare providers based on individual patient circumstances.

All trial data presented in this article are sourced directly from the published clinical trial report and its supplementary materials. Numbers are reproduced exactly as reported; no calculations, derivations, or estimates have been performed.

Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability.

Comparator trial data presented in Section 8 are sourced from their respective published reports and are provided for contextual purposes only. Cross-trial comparisons have inherent limitations and should not be interpreted as direct statistical comparisons.

References

1. Im S-A, Lu Y-S, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381:307-316. doi:10.1056/NEJMoa1903765
2. Kisqali (ribociclib) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
4. Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904-915.
5. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738-1748.
6. Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive, advanced breast cancer. N Engl J Med. 2015;373:209-219.
7. Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638-3646.